Alexandria Pharmaceuticals stock stayed 23.94 percent below its yearly high

Alexandria Pharmaceuticals (ISIN EGS38341C011) was last at EGP 1,511.26 on the Egyptian Exchange on October 6, 2026, 23.94 percent below its 52-week high of EGP 1,987.00. The latest audited annual result gives the market a second reference point, with fiscal 2025/2026 net profit of EGP 524.8 million.

Price remains below yearly high

The October 6 market page put the session range at EGP 1,500.50 to EGP 1,532.30, while the opening price was EGP 1,525.70. The difference between the last price and the yearly high shows that the stock was trading materially below its recent peak, even though the quotation remained well above the 52-week low of EGP 651.00 reported for September 17, 2026.

The price position matters because Alexandria Pharmaceuticals operates in a sector where earnings growth and regulated pricing can quickly change how investors value the shares. A gap of 23.94 percent to the yearly high leaves the stock sensitive to fresh operating figures, dividend decisions and any new company disclosure.

Profit rose to EGP 524.8 million

According to FoudaLens on September 28, 2026, audited net profit for the fiscal year ended June 30, 2026, reached EGP 524,799,762. The comparable figure for the fiscal year ended June 30, 2025, was EGP 391,169,831, putting the year-over-year increase at 34.16 percent.

The comparison is important for the stock because it links the market valuation to a clearly defined reporting period rather than to a short-term price move. The result also confirms that the company entered the new fiscal year with a higher profit base, although the published figures do not by themselves establish the direction of the next quarterly result.

Earlier profit target sets a benchmark

Arab Finance listed a company target of EGP 690 million in net profit for fiscal 2026/2027 in its April 14, 2026 company-news section. That target is a forward benchmark for the EGP 524.8 million audited result, while the stock price remains 23.94 percent below the EGP 1,987.00 yearly high.

For investors, the key tension is visible in the combination of a higher annual profit base and a share price below its recent peak. Alexandria Pharmaceuticals stock therefore remains tied to the next disclosed operating figure, with the fiscal 2025/2026 result providing the latest completed annual comparison.

Alexandria Pharmaceuticals stock below EGP 1,987.00

Alexandria Pharmaceuticals stock was last at EGP 1,511.26 on the Egyptian Exchange on October 6, 2026. The quotation stood 23.94 percent below its 52-week high of EGP 1,987.00.

More news and analyses on Alexandria Pharmaceuticals stock